Last checked at 2 Jun 2015 07:00
2 June 2015 |
PLANT HEALTH CARE plc
("Plant Health Care" or the "Company")
Plant Health Care Signs Innatus™ 3G Evaluation Agreement With Second Major Industry Player
Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce that it has signed an agreement with a second major industry player regarding the evaluation of its Innatus™ 3G peptide platform.
This technology enables the design, screening and production of a large pipeline of peptides with diverse bio-stimulant properties. The peptides can provide improved yields, pest and disease resistance, and protection against abiotic stress in a wide range of crops. Peptides can be combined with conventional crop protection chemicals in seed treatment and foliar applications, making them highly complementary to existing practices.
Paul Schmidt, CEO of Plant Health Care, commented, "Our goal was to sign at least two evaluation agreements for our Innatus™ 3G peptide platform this year and we have accomplished that within the first five months. We are targeting the largest players and these agreements reflect the potential value they see in our platform. Our dialogue with other major players is on-going."
- ENDS -
For further information, please contact:
Plant Health Care plc
Paul Schmidt, Chief Executive Officer Tel: +1 (919) 926 1600
Liberum Capital - Nomad and Broker
Clayton Bush Tel: +44 (0) 20 3100 2000
LHA
Ed McGregor / Jody Burfening Tel: +1 (212) 838 3777
Company website: www.planthealthcare.com
About Plant Health Care: Plant Health Care is a leading provider of novel patent-protected biological products to the global agriculture markets. In this way, Plant Health Care is capitalising on long-term trends toward natural systems and biological products for plant care and soil and water management. The Company's ordinary shares have been quoted on the AIM market of the London Stock Exchange since July 2004 (ticker symbol: PHC).